Genprex, Inc. (GNPX) reported that its research collaborators have published positive preclinical data for the NPRL2 tumor suppressor gene, utilizing the non-viral Oncoprex Delivery System, in KRAS/STK11 mutant anti-PD1 resistant non-small cell lung cancer in a humanized mouse model.